[Form 4] MOLINA HEALTHCARE, INC. Insider Trading Activity

Rhea-AI Filing Summary

Molina Healthcare Chief Operating Officer James Woys reported two equity-related transactions in company common stock. On March 1, 2026, 1,313 shares were disposed of to cover withholding taxes triggered by the vesting of 5,337 shares, using a price of $154.05 per share, leaving 73,018 shares directly held after this step.

On the same date, he received a grant of 17,016 restricted shares under the 2025 Equity Incentive Plan at $145.75 per share, based on a volume-weighted average price for the 10 trading days before March 1, 2026. These 17,016 shares vest in three equal installments on March 1, 2027, 2028, and 2029. Additional unvested tranches include 3,632 shares vesting on March 1, 2027 and 2,082 shares on March 1, 2028. After the grant, he directly held 90,034 shares.

Insights

Equity Compensation Analyst

Routine equity grant and tax withholding, with net increase in COO holdings.

The transactions for Molina Healthcare COO James Woys reflect normal equity compensation mechanics rather than open-market trading. A Form 4 code F shows 1,313 shares used to satisfy tax withholding from vesting of 5,337 shares, not a discretionary sale at market.

He simultaneously received a grant of 17,016 restricted shares under the 2025 Equity Incentive Plan at $145.75 per share, based on a 10-day VWAP. The disclosed vesting schedule staggers share delivery through March 1, 2029, tying compensation to ongoing service and performance conditions.

Following these movements, direct holdings increased to 90,034 shares. The net effect is an expansion of equity exposure through multi-year vesting, with cash-flow effectively limited to tax withholding. Subsequent company filings may provide further detail on future equity awards or changes in ownership levels.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WOYS JAMES

(Last) (First) (Middle)

2180 HARVARD STREET

SUITE 400

(Street)

SACRAMENTO CA 95815

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MOLINA HEALTHCARE, INC. [ MOH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		F		1,313(1)	D	$154.05(2)	73,018	D
Common Stock	03/01/2026		A		17,016(3)	A	$145.75(4)	90,034(5)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were applied to the payment of withholding taxes arising in connection with the vesting of 5,337 shares on March 1, 2026.

2. Represents the closing price of the Issuer's common stock on February 27, 2026.

3. Grant of restricted stock under the Issuer's 2025 Equity Incentive Plan.

4. Represents the volume-weighted average price (VWAP) of the Company's common stock for the ten (10) trading dates immediately preceding the March 1, 2026 grant date.

5. The shares shall vest as follows: The 17,016 newly granted shares shall vest in one-third increments on each of March 1, 2027, March 1, 2028, and March 1, 2029. Additional shares shall vest as follows: 3,632 shares on March 1, 2027; and 2,082 shares on March 1, 2028. The remaining shares are vested.

Remarks:

	Jeff D. Barlow, by power of attorney for James Woys	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.